Investigation of the risk factors to predict cytokine release syndrome in relapsed or refractory B-cell acute lymphoblastic leukemia patients receiving IL-6 knocking down anti-CD19 chimeric antigen receptor T-cell therapy

• Published in: Frontiers in immunology Vol. 13; p. 922212
• Main Authors: Gong, Wen-Jie, Qiu, Yan, Li, Ming-Hao, Chen, Li-Yun, Li, Yan-Yan, Yu, Jing-Qiu, Kang, Li-Qing, Sun, Ai-Ning, Wu, De-Pei, Yu, Lei, Xue, Sheng-Li
• Format: Journal Article
• Language: English
• Published: Frontiers Media S.A 29.08.2022
• Subjects: chimeric antigen receptor T-cell therapy; cytokine release syndrome; IL-6 knocking down; Immunology; relapsed or refractory B-cell acute lymphoblastic leukemia; risk factors
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2022.922212

CD19 chimeric antigen receptor-T (CAR-T) cell therapy has achieved remarkable results in patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). However, the cytokine release syndrome (CRS) was presented in most patients as common toxicity and severe CRS (sCRS) characterized by the sharp increase in interleukin-6 (IL-6) could be life-threatening. We conducted a phase II clinical trial of ssCAR-T-19 cells, anti-CD19 CAR-T cells with shRNA targeting IL-6, in 61 patients with r/r B-ALL. This trial was registered at www.clinicaltrials.gov as #NCT03275493. Fifty-two patients achieved CR while nine patients were considered NR. The median duration of response (DOR) and overall survival (OS) were not reached (>50 months). CRS developed in 81.97% of patients, including 54.10% with grades 1 to 2 (grade 1, 31.15%; grade 2, 22.95%) and 27.87% with grades 3 to 4 (grade 3, 26.23%; grade 4, 1.64%). sCRS occurs earlier than mild CRS (mCRS). A multivariable analysis of baseline characteristics identified high bone marrow disease burden and poor genetic risk before infusion as independent risk factors for sCRS. After infusion, patients with sCRS exhibited larger expansion of ssCAR-T-19 cells, higher peak levels of IL-6, IL-10, and IFN-γ, and suffered more severe hematological and non-hematological toxicities compared with those with mCRS.